Department of Medical Oncology, Cancer Centre of Southeastern Ontario & Queen's University, Kingston, Ontario, Canada.
Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre & Department of Medicine, University of Toronto, Toronto, Canada.
Future Oncol. 2018 Oct;14(25):2565-2577. doi: 10.2217/fon-2018-0101. Epub 2018 Jun 1.
Epithelial ovarian cancer (EOC) remains a leading cause of cancer death in women. Approximately 10-15% of patients with EOC harbor a genetic predisposition due to mutations in BRCA1/2 genes. In the recurrent setting, prolonging time to platinum-resistance may improve progression-free survival. In BRCA1/2 mutated ovarian cancer, the use of a polyadenosine diphosphate-ribose polymerase inhibitors has been studied in the maintenance and recurrent setting. In the pivotal Phase III NOVA trial, maintenance therapy post platinum response with niraparib significantly improved outcomes in all subgroups, leading to the first polyadenosine diphosphate-ribose polymerase inhibitors approval by the US FDA in this setting. In this review, we will focus on the role of niraparib in the treatment of EOC.
上皮性卵巢癌（EOC）仍然是女性癌症死亡的主要原因。大约 10-15%的 EOC 患者由于 BRCA1/2 基因突变而具有遗传易感性。在复发性疾病中，延长铂耐药时间可能会改善无进展生存期。在 BRCA1/2 突变卵巢癌中，聚腺苷二磷酸核糖聚合酶抑制剂已在维持和复发治疗中进行了研究。在关键的 III 期 NOVA 试验中，尼拉帕尼在铂类药物反应后的维持治疗显著改善了所有亚组的结局，这使得聚腺苷二磷酸核糖聚合酶抑制剂首次在美国食品和药物管理局（FDA）批准用于该治疗领域。在这篇综述中，我们将重点关注尼拉帕尼在 EOC 治疗中的作用。
